CAR-T Therapy Research Tools from CST

Over the past decade, immunotherapy has rapidly become what many call the “fifth” pillar of cancer treatments due to its ability to reduce, and even eradicate, tumors in some people with advanced cancer. 

Chimeric antigen receptor (CAR) T therapy is a revolutionary type of adoptive cell immunotherapy, which holds tremendous promise for many aggressive tumors. As the name implies, T cells are the backbone of CAR T-cell therapy. Currently available CAR T-cell therapies are customized for each individual patient and involve reprogramming the patient’s own immune system cells to target the cancer. CAR T-cell therapies are made by collecting T cells from the patient and reprogramming them in the lab to produce proteins on their surface called CARs. The CARs recognize and bind to specific antigens on the surface of cancer cells, and thereafter kills the cancer cells. 

The CAR-T Development Workflow 

The workflow for developing CAR T is a multi-step process that ensures the development of safe and effective treatments. Cell Signaling Technology (CST) offers product solutions for preclinical research for target identification and selection, CAR T-cell characterization, and response monitoring. 

First-to-Market CAR Detection Reagents for CAR-T Research: Anti-CAR Linker mAbs 

To aid in characterizing CAR-T cells, CST offers innovative and award-winning CAR Linker antibodies that target the G4S and Whitlow linker sequences of scFv-based CARs.  

Additionally, you can find fluorochrome-conjugated antibodies for CAR-T cell phenotyping and multiple IHC-validated monoclonal antibodies to analyze CAR targets in tissues. With a growing portfolio of related products, CST supports your CAR-T research, every step of the way. 

Advantages of CST® Anti-CAR Linker Antibodies: 

  • Designed to recognize a broad range of scFv-based CARs 
  • Specifically detect either: G4S Linker or Whitlow Linker 
  • Compatible with multiparametric flow panels 
  • Facilitate the monitoring of CAR expression, trafficking, and persistence 
  • Lot reservations and bulk orders available 

Anti-CAR linker antibodies

CST anti-CAR linker antibodies, against either the G4S or Whitlow linker, recognize exogenously expressed levels of scFv-based CARs. 



G4S Linker (E702V)

Whitlow/218 Linker (E3U7Q) 

Unconjugated#71645 #57710
Unconjugated, BSA & Azide Free#63670#66159
PE Conjugate#38907#62405
Alexa Flour® 488 Conjugate#50515#55809
Alexa Flour® 532 Conjugate#90841#25186
Alexa Flour® 555 Conjugate#18862#85651
Alexa Flour® 954 Conjugate#39614#61465
Alexa Flour® 647 Conjugate#69782#69310
Alexa Flour® 700 Conjugate#40107#72160

Anti-CAR Linker Panels

The CAR-T Cell Transduction Efficiency Flow Cytometry Panels can be used to identify conventional human T cell subsets that have been engineered to express scFv-based CARs containing a G4S or Whitlow linker. 



G4S Linker (E702V)

Whitlow/218 Linker (E3U7Q) 

CAR-T Cell Transduction Efficiency Flow Cytometry Panel#18839#35139

Want to know more?

CST offers a diverse array of antibodies against targets in relevant signaling pathways, enabling you to evaluate downstream outcomes and better understand CAR-T cell behavior. Download the CAR Signaling Network pathway and find out more. 

 Let's talk Science!  Reach out for more information!


Product Manager

Maria Kam Eriksen

+45 2244 8243


Product Manager